Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Martin Bautista

Internal Medicine Guymon, OK Medical Doctor

NPI 1144249327 CMS profile 279072

350 Ne 12Th St, Guymon, OK 73942

Open in the dashboard

General payments

$5,482

327 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Martin Bautista of Guymon, OK is reported in the CMS Open Payments database as having received $5,482 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $290 16
2024 General $380 19
2023 General $602 33
2022 General $888 56
2021 General $1,233 72
2020 General $1,160 70
2019 General $929 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Bautista
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Martin Bautista were reported at $290. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Martin Bautista Internal Medicine median Middle half National median
2019 $929 $159 $48–$570 $163
2020 $1,160 $119 $33–$402 $114
2021 $1,233 $135 $37–$521 $132
2022 $888 $141 $42–$496 $149
2023 $602 $149 $45–$519 $160
2024 $380 $154 $47–$537 $164
2025 $290 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,808 145 payments
  2. Merck Sharp & Dohme Corporation $544 44 payments
  3. Pfizer Inc. $300 18 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $261 19 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $228 15 payments
  6. Lilly USA, LLC $215 15 payments
  7. Novo Nordisk Inc $207 14 payments
  8. Xeris Pharmaceuticals, Inc. $121 7 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $119 8 payments
  10. Mylan Specialty L.P. $104 6 payments
  11. Other $573 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,465 325 payments
  2. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,378 61 payments
  2. SYMBICORT $640 37 payments
  3. BREZTRI $624 24 payments
  4. STEGLATRO $544 44 payments
  5. FASENRA $451 17 payments
  6. BELSOMRA $415 32 payments
  7. JANUVIA $384 33 payments
  8. BREZTRI AEROSPHERE $279 9 payments
  9. JARDIANCE $221 16 payments
  10. STEGLUJAN $216 18 payments
  11. Other $3,184 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

2,426

Median for Internal Medicine: 777

Drug cost

$155,493

Median for Internal Medicine: $73,373

Branded share of claims

16.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 37 $39,650
Farxiga Dapagliflozin Propanediol Brand 38 $24,245
Ozempic Semaglutide Brand 24 $19,897
Jardiance Empagliflozin Brand 21 $12,289
Tresiba Flextouch U-100 Insulin Degludec Brand 19 $9,168
Eliquis Apixaban Brand 12 $7,662
Januvia Sitagliptin Phosphate Brand 12 $7,469
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $7,257
Linzess Linaclotide Brand 11 $5,658
Dexlansoprazole Dr Dexlansoprazole Brand 14 $2,395

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$167,547

Of which drugs: $2,738

Medicare patients

207

Average age 74

Services billed

9,343

78 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 42%
Arthritis 37%
Ischemic heart disease 22%
COPD 21%
Heart failure 14%
Atrial fibrillation 13%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, nalbuphine hydrochloride, per 10 mg J2300 Office 53 502 $1,210
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 23 23 $493
Injection, ceftriaxone sodium, per 250 mg J0696 Office 97 1,099 $384
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 55 410 $258
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 116 2,072 $179
Injection, ketorolac tromethamine, per 15 mg J1885 Office 43 374 $179
Injection, midazolam hydrochloride, per 1 mg J2250 Office 35 155 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $69
$69 38 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $65
$65 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $36
$36 — —
YUPELRI
  • Mylan Specialty L.P. $36
$36 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record